<DOC>
	<DOCNO>NCT00096668</DOCNO>
	<brief_summary>This open label study patient receive TOCOSOL ( R ) Paclitaxel 120mg/m2 every week first line treatment metastatic breast cancer . Patients follow determine efficacy treatment ( measure objective response rate ) , safety associate weekly administration TOCOSOL Paclitaxel .</brief_summary>
	<brief_title>Evaluation Safety Efficacy TOCOSOL ( R ) Paclitaxel Initial Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description>This open label , non-randomized Phase 2 study weekly administration TOCOSOL Paclitaxel dose level , 120mg/m2 , know tolerate base Phase 2a study investigational agent patient histological diagnosis . This study fix sample size design plan early stopping decision . The goal study include determination safety TOCOSOL Paclitaxel , objective response rate , define RECIST criterion complete response plus partial response .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female patient histologic diagnosis breast carcinoma Stage IV ( M1 ) disease No prior cytotoxic chemotherapy regimen treatment metastatic breast cancer Adult ( 18 year age old ) patient Adequate hematologic function ( ANC &gt; =1500 cells/mm3 platelet &gt; 100,000/mm3 Serum creatinine &lt; =2.0 mg/dL Total bilirubin &lt; =1.5 mg/dL AST/SGOT ALT/SGPT &lt; =3 time upper limit institutional normal value PT PTT within institutional normal range ECOG performance status 02 At least one unidimensionally measurable lesion define RECIST criterion assessable radiographic evaluation A sign IRB/Ethics Committee approve Informed Consent Life expectancy least 12 week Fully recover previous surgery A negative pregnancy test prior study entry premenopausal Agree take Vitamin E supplementation receive study medication Any prior taxanecontaining chemotherapy include Taxol Taxotere Patients pregnant lactate Peripheral neuropathy NCICTC grade 2 great Widefield radiation , hormonal therapy trastuzumab within 4 week first dose study drug ; cytotoxic chemotherapy within 6 month first dose study drug Treatment investigational agent within 4 week first dose study drug Patients history carcinoma primary site distinguish histologically metastatic breast carcinoma Bone metastasis , effusion , ascites elevate tumor marker evidence metastatic breast carcinoma Brain metastasis Active bowel obstruction Active , serious infection serious medical problem ( metastatic breast cancer ) likely impair completion study protocol Concurrent therapy know substrate inhibitor cytochrome P450 isoenzymes CYP2C8 CYP3A4 Concurrent therapy warfarin coumarin derivative</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>TOCOSOL Paclitaxel</keyword>
</DOC>